Britni Hebert, MD
Internal Medicine · Lafayette, LANPI 1215198452
Payments from drug & device makers
Across 196 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$344
- AbbVie$282
- Pfizer$277
- Lilly USA, LLC$272
- Novo Nordisk$238
- AstraZeneca$234
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,072100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 22 | $344 |
| AbbVie(2 entities) | 17 | $282 |
| Pfizer | 16 | $277 |
| Lilly USA, LLC | 19 | $272 |
| Novo Nordisk | 15 | $238 |
| AstraZeneca | 17 | $234 |
| GSK | 10 | $177 |
| Abbott | 9 | $136 |
| Bayer | 6 | $95 |
| Novartis | 6 | $92 |
| Astellas Pharma US Inc | 5 | $80 |
| Exact Sciences | 4 | $74 |
| Sanofi Pasteur Inc. | 5 | $69 |
| Seqirus USA Inc | 4 | $65 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Boehringer Ingelheim | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Johnson & Johnson | 4 | $52 |
| Amarin Pharma, Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Biogen | 2 | $40 |
| Edwards Lifesciences | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Ardelyx, Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| Eisai Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
How this compares
$3,086 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 161 | $188,392 |
| EliquisApixaban | 107 | $82,773 |
| TrulicityDulaglutide | 68 | $68,378 |
| OzempicSemaglutide | 45 | $41,167 |
| MyrbetriqMirabegron | 48 | $34,203 |
| LinzessLinaclotide | 27 | $18,646 |
| XareltoRivaroxaban | 22 | $13,411 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 38 | $11,918 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 44 | $9,780 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,887 |
| Atorvastatin Calcium | 307 | $5,586 |
| Rosuvastatin Calcium | 420 | $5,549 |
| Pantoprazole Sodium | 210 | $4,968 |
| Levothyroxine Sodium | 462 | $4,853 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $272 | $256,770229 claims |
| PfizerEliquis | $277 | $82,773107 claims |
| Novo NordiskOzempic | $238 | $41,16745 claims |
| Astellas Pharma US IncMyrbetriq | $80 | $34,20348 claims |
| GSKArexvy, Shingrix, Breo Ellipta | $177 | $26,50994 claims |
| AbbVieLinzess, Synthroid | $282 | $22,96992 claims |
| Johnson & JohnsonXarelto | $52 | $13,41122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Lafayette
- Bryan LebeanLafayette$53K
- Nethuja SalagundlaLafayette$32K
- Himani Reddy ManthenaLafayette$28K
- Hector RoblesLafayette$19K
- Brad BroussardLafayette$17K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.